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Shp-2 is critical for ERK and metabolic engagement
downstream of IL-15 receptor in NK cells
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The phosphatase Shp-2 was implicated in NK cell development and functions due to its
interaction with NK inhibitory receptors, but its exact role in NK cells is still unclear. Here we
show, using mice conditionally deficient for Shp-2 in the NK lineage, that NK cell develop-
ment and responsiveness are largely unaffected. Instead, we find that Shp-2 serves mainly to
enforce NK cell responses to activation by IL-15 and IL-2. Shp-2-deficient NK cells have
reduced proliferation and survival when treated with high dose IL-15 or IL-2. Mechanistically,
Shp-2 deficiency hampers acute IL-15 stimulation-induced raise in glycolytic and respiration
rates, and causes a dramatic defect in ERK activation. Moreover, inhibition of the ERK and
mTOR cascades largely phenocopies the defect observed in the absence of Shp-2. Together,
our data reveal a critical function of Shp-2 as a molecular nexus bridging acute IL-15 signaling
with downstream metabolic burst and NK cell expansion.
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Natural killer (NK) cells are innate cytotoxic lymphocytespoised to eliminate infected or transformed cells. NK celleffector functions are tightly regulated by the balance of
activating and inhibitory signals. In healthy individuals, the bal-
ance is dominated by inhibitory signals. This is accomplished via
the recognition of self-molecules, such as major histocompat-
ibility (MHC) class I, by a variety of inhibitory receptors
expressed at their cell surface1,2. Interestingly, inhibitory receptor
engagement by MHC class I molecules, somewhat counter-
intuitively, is also required during NK cell development for
conferring optimal NK cell function1–4. In support of this, NK
cells from MHC class I-deficient animals are largely hypor-
esponsive to activating receptor-mediated stimuli4–6. NK cell
inhibitory receptor signaling is mediated by phosphatases,
including the SH2-containing inositol phosphatase-1 (SHIP-1)
and the crucial SH2 domain-containing tyrosine phosphatase-1
(Shp-1)7–11, which is recruited to the inhibitory receptor immu-
noreceptor tyrosine-based inhibitory motifs (ITIM) upon
engagement. Confirming the critical role of inhibitory receptor
engagement in NK cell education, Shp-1-deficient NK cells are
hyporesponsive.
Shp-2 (encoded by the gene Ptpn11) is a tyrosine phosphatase
that—together with its close relative Shp-1—belongs to the
family of SH2 domain-containing protein tyrosine phosphatases
(PTPs)12. Both phosphatases bear two SH2 domains in their N-
terminal part followed by a PTP domain responsible for the
catalytic activity. In the inactive state, the SH2 domains bind the
PTP region, thereby blocking access of substrates to the active
site. This auto-inhibition is relieved upon binding of the SH2
domains to phosphotyrosine residues on targets, including ITIMs
of inhibitory receptors, rendering the catalytic site accessible12.
As shown by the embryonic lethality of full-body deleted mice,
Shp-2 plays essential developmental functions, being involved in
cell growth, differentiation, proliferation, and survival12. In
humans, SHP-2 loss-of-function results in Leopard syndrome, a
severe disease marked by skeletal malformation, short stature,
heart disease and mental retardation. SHP-2 gain-of-function
mutations result in Noonan syndrome, which shares clinical
features with Leopard syndrome13. Shp-2 exerts atypical effects,
as it has mainly been ascribed positive roles in regulating growth
factor and hormone receptor signaling. The best-characterized
functions of Shp-2 are the positive regulation of the mitogen-
activating protein kinases (MAPK) and—to some extent—the
modulation of the phosphoinositide 3-kinase (PI3K)-
Akt and mammalian target of rapamycin (mTOR) pathway
downstream of various growth factor receptors in different
tissues12,14–18. Shp-2 has therefore been proposed to depho-
sphorylate negative regulators of the MAPK pathway12. Along
these lines, SHP-2 overactivation is involved in cancer develop-
ment and novel inhibitors have been developed to treat these
malignancies19,20. Last, as SHP-2 has been shown to interact with
the ITIMs of NK cell inhibitory receptors21,22, an inhibitory role
in NK cells was predicted. However, this assumption has not been
experimentally confirmed.
Because Shp-2 is required for embryonic development, we
generate mice conditionally deficient for Shp-2 in the NK lineage.
In contrast to Shp-1 and SHIP-1 phosphatases, we find that Shp-2
is largely dispensable for NK cell education. Instead, the absence
of Shp-2 is disadvantageous when NK cells are exposed to high
IL-15 doses. This phenotype is linked to a markedly impaired
engagement of ERK and to a compromised metabolic activation.
In agreement with these findings, Shp-2-deficient Ly49H+ NK
cells have defective proliferation during MCMV infection. Taken
together, these data uncover an unanticipated role of Shp-2 in NK
cells, identifying this phosphatase as an essential node in NK cell
metabolism downstream of the IL-15 receptor.
Results
Ncr1cre Ptpn11fl/fl mice exhibit increased NK cell numbers.
Ptpn11 is expressed in NK cells, as shown by measuring transcript
abundance in developing bone marrow (BM) as well as splenic
NK cells of intermediate CD27+CD11b+ (DP) and mature CD27
−CD11b+ (CD11b SP) stage (Supplementary Fig. 1a). We thus
sought to determine the contribution of Shp-2 to NK cell
development and functions by generating two independent NK
cell-specific knockout lines. In one case, Ptpn11fl/fl (exons 3 and
4) mice were crossed to the Ncr1creKi deleter strain (knock-in for
a Cre recombinase under the control of the Ncr1 promoter, which
is active in NK cells at the immature-mature stage; hereafter
referred to as Ncr1Ki Ptpn11fl/fl)15,23. This led to a virtually
complete Shp-2 deletion in NK cells (Supplementary Fig. 1b). In
the second case, Ptpn11fl/fl (exon 11) mice were bred with the
Ncr1creTg deleter strain (transgenic for Cre under the control of
the Ncr1 promoter; hereafter referred to as Ncr1Tg Ptpn11fl/fl)24,25.
As the efficiency of Cre-mediated deletion in this model was not
complete, these mice were further crossed to a reporter strain
expressing YFP upon Cre recombinase activity, which faithfully
paralleled Shp-2 deletion (Supplementary Fig. 1c).
We next assessed the abundance of NK lymphocytes in the
spleen of Ncr1Ki Ptpn11fl/fl and Ncr1Tg Ptpn11fl/fl mice. Interest-
ingly, and in contrast to Shp-1 deficient animals7, we found that
NK cell frequency and number were higher in mice conditionally
deficient for Shp-2 in the NK lineage than in controls (Fig. 1a, b).
We next assessed whether this phenotype was observed during
their development. No significant differences were observed in
percentages and numbers of CD122+ NK cells, as well as in their
developmental stages, as measured by the sequential acquisition
of NK1.1 and DX5 in the bone marrow (BM) of Ncr1Ki Ptpn11fl/fl
mice or Ncr1Ki Ptpn11wt/wt controls (Supplementary Fig. 1d and
e). However, maturation of Shp-2-deficient BM NK cells was
slightly altered, exhibiting increased percentages and numbers of
the most mature CD11b SP subset (Fig. 1c). We also analyzed the
maturation status of NK lymphocytes in spleen and liver. Similar
to the BM, frequency and number of CD11b SP NK cells were
higher than in controls in the spleen of both Shp-2-deficient
models, and in the liver (Fig. 1d, e, and f). In the liver, similarly to
other organs, conventional NK cell frequency and number were
increased. In contrast, ILC1 (CD49a+DX5−) frequency and
number were decreased (Supplementary Fig. 1f). Importantly,
mixed BM chimeras demonstrated that Shp-2 controlled the
numbers of mature NK cells in a cell-intrinsic manner
(Supplementary Fig. 1g). Taken together, data from two
independent mouse models show that Shp-2 limits the number
of the most mature NK cell subset.
Shp-2-deficient NK cells are educated. Because inhibitory
receptors expressed on NK cells have been shown to recruit
Shp-2, we investigated the education state of NK cells lacking this
phosphatase21,22. We first characterized the receptor repertoire,
which exhibits increased levels of Ly49 inhibitory receptors and
decreased expression of KLRG1 in non-educated NK cells, as
exemplified by NK cells derived from β2 m−/− mice (Fig. 2a).
However, Shp-2 deficiency did not cause such changes, allowing
expression of a largely normal repertoire (Fig. 2a).
To assess the role of Shp-2 in NK cell effector functions, we
first measured their ability to produce cytokines and cytotoxic
mediators in response to phorbol 12-myristate 13-acetate (PMA)/
ionomycin stimulation. No defects in Granzyme A (GzmA),
GzmB, or degranulation (quantified by surface CD107α) were
observed (Fig. 2b). We then examined the effector response to
“missing-self” targets and induced by engagement of two well
characterized NK cell activating receptors, NKG2D and Ly49H.
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We performed an in vitro killing assay using RMA cells (H-2b)
and variants lacking MHC class I (RMA-S), or bearing the
NKG2D ligand H60 (RMA-H6026) as targets. We found that Shp-
2-deficient and wild-type in vivo primed NK cells killed RMA-S
and RMA-H60 to comparable extents (Fig. 2c). Using RMA cells
transfected with the Ly49H ligand M157, we observed that Shp-2-
deficient and wild-type Ly49H+ NK cells exhibited comparable
degranulation levels (Fig. 2d). Taken together, these data
demonstrate that the absence of Shp-2 does not impair NK cell
effector functions. This contrasts with the hyporesponsive
phenotype of both SHIP-1 and Shp-1 deficient NK cells7–11.
Role of Shp-2 in response to IL-15. Our finding that Shp-2-
deficient mature NK cells were increased in numbers as compared
with control NK cells led us to investigate their response to IL-15,
which is essential for NK cell proliferation and survival27. We first
assessed the expression of the IL-15 receptor (IL-15R) chains on
Ptpn11-deficient and control NK cells28. Both common γ subunit
(γc; CD132) and IL-15Rβ chain (CD122) were expressed at normal
levels, ruling out a defect of IL-15 receptor cell surface expression
(Supplementary Fig. 2a and b). We next investigated whether the
response of Shp-2-deficient NK cells to IL-15 was altered. At low
IL-15 concentration Shp-2-deficient NK cells presented a survival
advantage, as shown by the increased number of recovered cells
(Fig. 3a) and the lower percentage of dying cells (propidium iodide
(PI)+; Fig. 3b). Conversely, high IL-15 concentration was detri-
mental to these cells, as observed both at 7 ng/ml, in the absence of
cell division, as well as at 50 ng/ml, in the presence of proliferation,
as shown by cell trace Violet (CTV) and PI staining (Fig. 3a, b).
Notably, the defective expansion of NK cells was also observed in
response to high doses IL-2 (Fig. 3c, d).
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Fig. 1 Loss of Shp-2 leads to increased mature NK cell numbers. a, b Representative flow cytometric image, frequency, and number of splenic NK cells
(gated as NK1.1+CD3/CD19−) of Ncr1Ki Ptpn11fl/fl (dark gray) and control mice (white) are depicted (a) or of splenic NK cells (gated as NK1.1+CD3−YFP
+NKp46+) of Ncr1Tg Ptpn11fl/fl (light gray) or Ncr1Tg Ptpn11wt/fl (white) mice (b) are depicted. c, d Analysis of NK cells from Ncr1Ki Ptpn11fl/fl and control
mice. c Representative cytometric plot of BM NK cells (gated as CD122+NK1.1+NKp46+CD3/CD19−) stained with CD27 and CD11b; percentage and
number of CD27 single-positive (CD27 SP; CD27+CD11b−), double-positive (DP; CD27+CD11b+), and CD11b single-positive (CD11b SP; CD27−CD11b+)
populations are shown. d Representative cytometric plot of splenic NK cells (gated as NK1.1+ NKp46+CD3/CD19−) stained with CD27 and CD11b;
percentage and number of the afore-mentioned subsets are shown. e As in (d), but for NK cells gated as NK1.1+CD3−YFP+NKp46+ from Ncr1Tg Ptpn11fl/fl
or Ncr1Tg Ptpn11wt/fl mice. f Frequency and number of CD27 SP, DP, and CD11b SP conventional NK cells (gated as CD45+NK1.1+CD3−YFP+NKp46+DX5
+CD49a−) from Ncr1Tg Ptpn11fl/fl and control mice in the liver and a representative staining of CD27 and CD11b expression. a, b Results represent the
mean ± SEM of n= 8 (Ncr1Ki Ptpn11fl/fl) and n= 13 (Ncr1Ki Ptpn11wt/wt) (a), n= 29 (Ncr1Tg Ptpn11wt/fl) and n= 35 (Ncr1Tg Ptpn11fl/fl) (b) mice per genotype,
are a pool of three (a) and nine (b) experiments, which are representative of at least five (a) and eleven (b) independent experiments. c–f Results represent
mean ± SEM of n= 4 (Ncr1Ki Ptpn11fl/fl) and n= 6 (Ncr1Ki Ptpn11wt/wt) (c), n= 7 (Ncr1Ki Ptpn11fl/fl) and n= 10 (Ncr1Ki Ptpn11wt/wt) (d), n= 29 (Ncr1Tg
Ptpn11wt/fl) and n= 35 (Ncr1Tg Ptpn11fl/fl) (e), and n= 16 (Ncr1Tg Ptpn11wt/fl) and n= 20 (Ncr1Tg Ptpn11fl/fl) (f) mice per genotype, are a pool of two (d), nine
(e, f) experiments and representative of at least three (c, d), and eleven (e, f) independent experiments. Statistical comparisons are shown; *p≤ 0.05,
**p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001, NS, non-significant; Student’s t-test. Source data are provided as a Source Data file
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The survival advantage at low IL-15 doses was consistent with
the accumulation of Shp-2-deficient NK cells observed under
physiological conditions in vivo (Fig. 1). Given the important role
of the antiapoptotic protein B cell leukemia/lymphoma 2 (Bcl-2)
in sustaining survival of resting NK lymphocytes29, we next
determined its expression level in knockout and control NK cells.
We found that Shp-2 deficient NK cells expressed higher Bcl-2
levels than control NK cells (Supplementary Fig. 2c). Interest-
ingly, while Bcl-2 expression decreased throughout maturation of
wild-type NK cells, it remained constant in Shp-2-deficient NK
lymphocytes, in agreement with the increased numbers of the
CD11b SP subset (Supplementary Fig. 2d). To validate these
findings, we assessed the effects of the Bcl-2 inhibitor ABT-199
on survival of co-cultured Shp-2-deficient and control NK cells.
Bcl-2 inhibitor treatment preferentially affected the survival of the
former, as shown by the decrease of the ratio of living Shp-2-
deficient over control NK cells (Fig. 3e). Furthermore, inhibition
of myeloid cell leukemia sequence 1 (Mcl1), a second major
antiapoptotic protein, did not revert the survival advantage of
Shp-2-deficient cells (Supplementary Fig. 2e) at low IL-15
concentrations, underscoring the contribution of Bcl-2.
We next wondered whether the effects of Shp-2 deficiency in
presence of low and high IL-15 concentrations were recapitulated
by supplying the Shp-2 inhibitor SHP099 to wild-type NK cell
cultures20. While SHP099 decreased NK cell expansion at high IL-
15 doses, it did not increase their survival in the presence of low IL-
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Fig. 2 Shp-2 is largely dispensable for NK cell effector functions. a Graphs depict percentages of CD94+, Ly49A+, Ly49G2+, Ly49I+, Ly49D+, Ly49H+,
and KLRG1+ splenic NK cells (gated as NK1.1+ CD3/CD19−) from Ncr1Ki Ptpn11wt/wt (white), Ncr1Ki Ptpn11fl/fl (dark gray), and B2m−/− (green) mice.
b Graph and a representative cytometric plot illustrate the production of granzyme A and B by splenic NK cells (gated as NK1.1+NKp46+CD3/CD19−) after
phorbol 12-myristate 13-acetate and ionomycin stimulation (PMA/Iono). c NK cells isolated from polyinosinic:polycytidylic acid (polyI:C)-treated Ncr1Ki
Ptpn11wt/wt or Ncr1Ki Ptpn11fl/fl mice were plated with RMA, RMA-S, or RMA-H60 cells at the indicated ratios. The graph depicts percentage killing of target
cells, as measured by quantifying PI− living target cells. d Naive splenocytes from Ncr1Tg Ptpn11fl/fl (light gray) mice or heterozygote littermate controls
(white) were incubated with RMA cells or RMA-m157 cells (expression of m157 is illustrated in the graph on the left). Percentage of YFP+Ly49H+CD107α
+ NK cells in each group was determined by flow cytometry (illustrated in the graph on the right). a, b Results represent the mean ± SEM of n= 4 (Ncr1Ki
Ptpn11fl/fl or B2m−/−) and n= 6 (Ncr1Ki Ptpn11wt/wt) mice per genotype and are representative of at least three (a) and two (b) independent experiments.
c, d Results represent the mean ± SD of n= 3 (c), n= 4 (for non-stimulated conditions) and n= 5 (for RMA conditions) (d) technical replicates and are
representative of at least two (c) and three (d) independent experiments. Statistical comparisons are shown; *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤
0.0001, NS, non-significant; Student’s t-test. Source data are provided as a Source Data file
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15 concentrations (Fig. 3f). This suggests that the survival advantage
of Shp-2-knockout NK cells reflects an adapted state of these cells to
their defective condition in vivo, rather than a direct effect of Shp-2
activity, and we thus focused on the effects at high doses.
Shp-2 supports features linked to NK cell activation. Our
findings that the survival and expansion of Shp-2-deficient NK
cell were impaired at high IL-15 doses (Fig. 3a, b) led us to
investigate whether the absence of Shp-2 affected NK cell acti-
vation by acute IL-15 exposure. Under these conditions, NK
lymphocytes acquire a blastoid morphology with increased
granularity. We thus examined the morphology of Shp-2-
deficient and control NK cells cultured in the presence of var-
ious IL-15 doses. Although the size and, in particular, the
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granularity of Shp-2-deficient NK cells augmented in response to
IL-15 (Fig. 4a), they increased significantly less than in wild-type
NK cells. This difference was mainly due to non-divided Shp-2-
deficient cells (Fig. 4b), suggesting that cell division occurred after
reaching a given size and granularity. To better understand this
phenomenon, we assessed cell cycle entry and granularity when
cells are starting to divide. The proliferation marker Ki67 was
expressed in highly granular cells (Fig. 4c). Furthermore, highly
granular, non-divided Shp-2-deficient NK cells were significantly
reduced as compared with the control counterparts (Fig. 4c), but
not the proportion of Ki67+ NK cells among them (Fig. 4d). This
indicates that, in Shp-2-deficient cells, the division defect in
response to IL-15 correlates with the granularity defect.
These results prompted us to analyze size and granularity of
Shp-2-deficient NK cells under physiological conditions in naive
animals. We found that NK cells from BM and spleen of Ncr1Ki
Ptpn11fl/fl mice were significantly affected in both parameters
(Supplementary Fig. 3a and Fig. 4e), especially in the CD11b SP
NK cell stage (Supplementary Fig. 3b and Fig. 4f). This phenotype
was also observed in splenic CD11b SP NK cells from the Ncr1Tg
Ptpn11fl/fl line (Supplementary Fig. 3c and d). Importantly, the
defect was cell-intrinsic as the decreased size and granularity was
conserved in Shp-2-deficient NK cells from mixed BM chimeric
mice (Supplementary Fig. 3e and f). Altogether, these results
suggest a role for Shp-2 in NK cell metabolism, alike what has
been established in a variety of non-immune tissues.
Shp-2 mediates metabolic rewiring in response to high IL-15.
Similar to other immune cells, metabolic activation was recently
revealed to be a critical event in NK cell activation, proliferation
as well as survival30. The results described above led us to
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hypothesize that the expression of Shp-2 might orchestrate
proper NK cell metabolic activity following exposure to IL-15. By
examining cellular metabolic activity with Seahorse technology,
we found that basal and maximal glycolytic rate of Shp-2-
deficient NK cells (as shown by extracellular acidification) were
reduced (Fig. 5a). This suggested that Shp-2-deficient NK cells
failed to engage aerobic glycolysis to support their expansion. In
addition, Shp-2-deficient NK cells also displayed reduced basal
oxygen consumption and spare respiratory capacity as measured
by oxygen consumption rates (OCR) (Fig. 5b), indicating that
they might lack the ability to adjust mitochondrial activity for
energy production in response to metabolic stress. Taken toge-
ther, these results demonstrate that Shp-2-deficient NK cells were
unable to properly raise both glycolytic and oxidative phos-
phorylation capacities in response to IL-15, which may contribute
to their phenotypic defects.
Shp-2 is a key mediator of IL-15-induced ERK activation. To
gain insight into the molecular mechanisms leading to the altered
IL-15 response of Shp-2-deficient NK cells, we investigated the
different known IL-15-dependent signaling pathways. These
include the engagement of Janus kinase (Jak)-Signal transducer
and activator of transcription (STAT) 5, mTOR, and extracellular
signal-regulated kinases (ERKs) (Fig. 6a)27,30–34. Whereas Shp-2-
deficient NK cells had nearly normal levels of STAT5 phosphor-
ylation after 30min of IL-15 stimulation, phosphorylation of S6, a
target of mTOR complex 1 (mTORC1)30,33–36, was strongly
decreased while phosphorylation of ERK was abrogated (Fig. 6b).
To ensure that the results were not biased by the different
composition of the NK cell maturation subsets, we assessed their
respective phosphorylation status of S6 and ERK by flow cyto-
metry. We found that signaling defects were present in all NK cells,
irrespective of the maturation stage (Fig. 6c). Similar signaling
defects were witnessed after 1 h of IL-15 stimulation, with the
exception of ERK, whose induction is too weak to be robustly
detected (Supplementary Fig. 4a). Importantly, Shp-2-deficient NK
cells exhibited lower basal levels of S6 and ERK phosphorylation,
indicating that Shp-2 constitutively contributed to these pathways,
likely downstream of endogenous IL-15 (Fig. 6c).
In order to exclude indirect effects of Shp-2 deficiency, we
assessed phosphorylation of S6 and ERK following stimulation
with PMA/ionomycin, which bypasses receptor proximal signal-
ing. We observed normal engagement of these pathways in Shp-
2-deficient NK cells (Supplementary Fig. 4b). We next stimulated
wild-type NK cells with IL-15 in the presence or absence of the
Shp-2 inhibitor SHP099. In agreement with the genetic approach,
we observed a virtually normal engagement of the Jak-STAT5
pathway, but a severe defect in ERK and S6 phosphorylation
(Fig. 6d). To corroborate the in vitro results, we assessed the
in vivo role of Shp-2 in response to stimulation with IL-15/IL-15R
complexes37. One-day post-treatment, we evaluated IL-15
signaling in NK cells ex vivo. In agreement with the in vitro
studies, we found that control NK cells presented prominent
phosphorylation of ERK and S6, while their Shp-2-deleted
counterparts displayed a strong defect in these signaling pathways
(Fig. 6e). Taken together, these results demonstrate that—
downstream of IL-15R—Shp-2 is required for ERK and,
presumably, mTORC1 engagement30,33–36.
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mTOR and ERK contribute to IL-15-driven NK cell expansion.
We next wondered whether the effect of Shp-2 on S6 phos-
phorylation is mediated by ERK. ERK has been reported to
suppress the mTORC1 inhibitor tuberous sclerosis complex
(TSC), thereby activating the mTORC1 pathway, and can further
regulate S6 phosphorylation through 90 kDa ribosomal S6
kinase38–40. We therefore assessed the effects of the mitogen-
activated protein kinase kinase (MKK/MEK) inhibitor PD98059
on S6 phosphorylation. PD98059 partially reduced S6 phos-
phorylation induced by IL-15 exposure, while it had no effect on
STAT5 (Fig. 7a). Importantly, in agreement with previous find-
ings30, Torin2, an inhibitor of mTORC1 and mTORC2, com-
pletely prevented S6 phosphorylation (Fig. 7a). We also assessed
the phosphorylation of Akt at position 308, which is regulated by
PI3K and contributes to Akt-mediated inactivation of the TSC
complex and the subsequent mTORC1 activation41. Interestingly,
we found that Akt phosphorylation at position 308 was largely
dependent on Shp-2 after 30 min and 1 h of stimulation (Fig. 7b
and Supplementary Fig. 5a). Altogether, these data suggest that
Shp-2 regulates PI3K-Akt and ERK engagement, which might
further contribute to mTORC1 and S6 activation (Supplementary
Fig. 5b).
To test whether defective ERK and mTORC1 signaling in Shp-
2-deficient cells account for the proliferation and the survival
defects observed in response to high IL-15 (Fig. 3a, b and Fig. 4c,
d), we cultured wild-type NK cells for 4 days in the presence of
PD98059 or Torin2. These inhibitors were supplied at low
concentrations in order to minimize aspecific effects. Reducing
the activity of ERK and, most prominently, mTOR led to
decreased proliferation and lower numbers of living NK cells
(Fig. 7c). In addition, a reduction of NK cell size and granularity
was observed (Fig. 7d). Taken together, these data support the
hypothesis that signaling by mTOR and ERK contribute to the
effects of Shp-2 in response to IL-15.
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Loss of Shp-2 affects MCMV-induced NK cell expansion. To
study the effects of endogenous IL-15 in vivo, we examined NK
cell homeostatic proliferation following adoptive transfer into
lymphopenic animals42,43. CPD-labeled NK cells isolated from
Ncr1Tg Ptpn11fl/fl were mixed at a 1:1 ratio with congenically
marked B6.SJL NK cells and co-transferred into Rag2−/−Il2Rg−/−
recipients. We found that wild-type NK cells divided significantly
more than Shp-2-deficient NK cells (Fig. 8a), confirming an
essential role of Shp-2 in IL-15-driven proliferation in vivo.
However, despite their impaired division, Shp-2-deficient NK
cells were overrepresented (Fig. 8b), consistent with their survival
advantage at low IL-15 doses (Fig. 3) and increased numbers at
steady state in vivo (Fig. 1).
To dissect Shp-2 contrasting roles in a more defined and
physiologically relevant infectious setting, we took advantage of
the well characterized MCMV model44–46. In this model,
engagement of the activating receptor Ly49H by the MCMV
protein m157 leads to preferential expansion of Ly49H+ NK cells,
as Ly49H signaling amplifies the response to IL-15 (Supplemen-
tary Fig. 6a)44. We reasoned that the absence of Shp-2 may be
disadvantageous for the Ly49H+ NK cells, but might improve the
survival of Ly49H− NK cells. To test this hypothesis, NK
cells isolated from Ncr1Tg Ptpn11fl/fl were mixed at a 1:1 ratio
with B6.SJL NK and transferred into NK cell-deficient mice
(Ncr1creKiROSA-DTA mice), which were simultaneously infected
with MCMV. Seven days post-infection, Shp-2-deficient and
control donor NK cells were found at the same ratio (Fig. 8c).
However, wild-type NK cells were overrepresented in the Ly49H+
subset, while Shp-2-deficient NK cells in the Ly49H− subset
(Fig. 8d). These data illustrate the importance of Shp-2 in
calibrating IL-15-induced signaling to optimize a specific NK cell
response during viral infection.
Discussion
The effects of Shp-2 on NK cell development and functions have
not been defined. Using two different mouse lines conditionally
deficient for Shp-2 in the NK lineage, we found that NK cell
development appeared for the most part normal, with the
exception of an increased number of the most mature NK cells.
Unexpectedly, we also observed that NK cell effector functions
were not impaired in these animals. Shp-2 binding to phos-
phorylated ITIMs has been well documented, in particular in the
context of T-cell inhibitory receptors21,22,47–49. However, its
in vivo function in both NK and T cells is less clear. In fact, we
recently reported that genetic deletion of Ptpn11 did not revert
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the dysfunctional state of exhausted T cells50. Altogether, these
data suggest that redundant mechanisms compensate for Shp-2
absence and that Shp-2 fulfills other functions in these cells.
The importance of Shp-2 in controlling the development of
several organs and tissues by relaying signaling from growth
factor receptors to MAPKs is well-established12,17,51. In NK cells,
activation of this pathway, as well as metabolism and proliferation
are tightly regulated by selected cytokines, especially IL-1527,30–33.
We therefore investigated whether Shp-2 regulated the NK cell
response to IL-15. Notably, we found that, in the absence of Shp-
2, IL-15-induced MAPK signaling was abolished. Our data fur-
ther suggest that Shp-2 is important for metabolic activation
through regulation of the PI3K-Akt-mTORC1 axis, although the
relevance of the Akt-mTORC1 connection in NK cells remains to
be clarified35,41, or indirectly through its effects on ERK.
Over a decade ago, recruitment of Shp-2 to the IL-15 receptor
was shown in response to IL-2 and IL-15 in both T and NK cells
and a positive role for Shp-2 in ERK activation was observed
downstream of IL-2 receptor in fibroblasts52–55, supporting our
data on the importance of Shp-2 downstream of the IL-15 and IL-
2 receptors. However, Shp-2 deficiency does not phenocopy the
NK cell defects observed in IL-15- and PI3K-deficient mice or in
mice conditionally deficient for mTORC1 and mTORC2 in the
NK lineage30,34,43,56. In these mouse models, NK cells present
severe developmental, maturation, and numerical defects, while
Shp-2 deficiency leads to rather increased numbers of the most
mature NK cells. Regarding the mechanism, we have unveiled
that Shp-2 uncouples the Jak-STAT5 from the ERK pathway and
future investigations are required to more precisely define the
intersection of Shp-2 with the totality of the signaling cascades
induced by IL-15.
It has been recently reported that constitutive metabolic over-
activation is detrimental for NK cell development and survival
in vivo57,58. NK cells lacking Tsc1 exhibited an overactive phe-
notype and underwent apoptosis57. In addition, NK cells deficient
for the transcription factor Rfx7 presented an increased metabo-
lism and were preferentially lost at physiological/limiting cytokine
concentrations, while had a survival advantage at high IL-15
doses58. These findings mirror the results described here, showing
that the lowered metabolic state of Shp-2-deficient NK cell helps
their maintenance and accumulation both in vivo and at low IL-15
concentrations in vitro, while is unfavorable at high IL-15 doses. In
line with these results, NK cell responses to low IL-15 doses are
dominated by the Jak-STAT5 pathway, which is nearly normal in
the absence of Shp-230. Similarly to NK cells deficient for 3-
phosphoinositide-dependent kinase 1 (PDK1), an upstream acti-
vator of mTORC1, Shp-2-deficient NK cells express higher levels
of Bcl-2, which supports their survival29,41,59. This antiapoptotic
protein was particularly abundant in the CD11b SP subset, strongly
correlating with their accumulation. However, the increased sur-
vival at limiting IL-15 doses was not recapitulated by in vitro
treatment of wild-type NK cells with the Shp-2 inhibitor. This
discrepancy could be explained by broader effects of the inhibitor
or suggest that this phenotype reflects an adaptation occurring
during development in vivo, a point that might be relevant with
respect to long-term treatment with Shp-2 inhibitors.
Not surprisingly, given the impaired signaling pathways, Shp-2
deletion affected the metabolic reprogramming of NK cells, which
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presented lower glycolysis, oxidative phosphorylation, as well as
spared respiratory capacity following IL-15 exposure. As a con-
sequence, Shp-2 deficient NK cells failed to increase their cellular
mass and granularity and did not divide at high IL-15 doses.
Importantly, this expansion defect was recapitulated upon IL-2
stimulation and during MCMV infection in Ly49H+ NK cells,
which have augmented sensitivity to IL-1544.
Altogether, our data demonstrate that Shp-2 is critical in the
context of acute IL-15 stimulation and in the presence of an
activating co-stimulus in vivo. We therefore propose that Shp-2
main function in NK cells is not to calibrate the threshold of NK
cell reactivity but instead to mediate IL-15 signaling, actively
favoring specific NK cell responses. A growing number of clinical
studies aim to harness NK cell anti-tumor immunity, while
selective Shp-2 inhibitors have been developed for treatment of
cancers relying on this pathway60. Based on our data, we argue
that therapeutic approaches combining Shp-2 inhibition with NK
cell stimulating regimens should be reevaluated and possibly
avoided. The use of this inhibitor might instead be beneficial in
the management of the aggressive large granular lymphocyte
leukemia, which has been proposed to depend on IL-1561–63.
Methods
Mice. NK cell-specific knockout mice for Ptpn11 were generated by crossing either
the Ptpn11fl/fl mice15 to the Ncr1creKi deleter strain23 or the Ptpn11fl/fl mice24 to the
Ncr1creTg mice64, generating Ncr1KiPtpn11fl/fl and Ncr1Tg Ptpn11fl/fl, respectively.
Ncr1creTg Ptpn11fl/fl mice were crossed to R26R-EFYP mice to monitor cre activity.
For genotyping Ncr1KiPtpn11fl/fl mice, Ptpn11-floxed alleles were detected by
PCR amplification using a set of two primers that amplify a 300 bp wt band and a
380 bp floxed band (forward primer 5′-ATGACTCCTGAAGCCCATTG-3′ and
reverse primer 5′-TTCCCATCACCTCAGACTCC-3′). For genotyping Ncr1Tg
Ptpn11fl/fl mice, Ptpn11-floxed alleles were detected by PCR amplification using a
set of two primers that amplify a 312 bp wt band and a 430 bp floxed band (forward
primer 5′-TAGCTGCTTTAACCCTCTGTGT-3′; reverse primer 5′-CATCAGA
GCAGGCCATATTCC-3′).
Ptpn11fl/fl15, Ncr1creKi, B6.SJL, β2m−/−, and C57BL/6 mice, all on a C57BL/6
(H2b) background, were bred under specific pathogen-free conditions at the animal
facility of the University of Lausanne. Sex- and age-matched 6–14-week-old mice
were used for the experiments. All animal experimental protocols were approved
by the Veterinary office regulations of the State of Vaud, Switzerland, and all
methods were performed in accordance with the Swiss guidelines and regulations.
C57BL/6, B6.SJL (B6.SJL-Ptprca Pepcb/BoyJ), R26R-EFYP (B6.129×1 Gt(ROSA)
26Sortm1(EYFP)Cos/J), and ROSA-DTA (B6.129P2-Gt(ROSA)26Sortm1(DTA)Lky/J)
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Rag2−/−Il-
2Rg−/− (B10;B6-Rag2tm1Fwa Il2rgtm1Wjl) mice were purchased from Taconic
Biosciences (Germantown, NY). Ptpn11fl/fl24, Ncr1creTg25 and the above-
mentioned mice were bred in pathogen-free facilities at Brown University. For
MCMV experiments, the ROSA-DTA mice were crossed to Ncr1creKi mice to
generate Ncr1creKi ROSA-DTA recipient mice, which are deficient in NK cells. Sex-
and age-matched 6–12-week-old mice were used for the experiments. The studies
performed at Brown University were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals, as
defined by the National Institutes of Health (PHS Assurance #A3284-01). Animal
protocols were reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) of Brown University. All animals were housed in a
centralized and AAALAC-accredited research animal facility that is fully staffed
with trained husbandry, technical, and veterinary personnel.
Mixed bone marrow chimeras. Donor BM cells were obtained from sex-matched
control mice (CD45.1/2) and Ncr1Ki Ptpn11fl/fl mice (CD45.2) by flushing femurs
and tibias and mixed in a 1:1 ratio. A total of 5 × 106 BM cells were injected
intravenously into recipient mice (CD45.1), which had been previously lethally
irradiated with 900 rad. The recipients were allowed to reconstitute for at least
6 weeks. Frequency of CD45.2 and CD45.1/2 NK cells was determined by flow
cytometry.
Murine lymphocytes isolation. For what concerns Ncr1KiPtpn11fl/fl data: sple-
nocytes were obtained by mechanical disruption of the spleen and bone marrow
cells were obtained by flushing femurs. Red blood cells were lysed.
For what concerns Ncr1TgPtpn11fl/fl data: mice were sacrificed with isoflurane.
Cardiac puncture was performed prior to organ removal. Spleens were processed
with a GentleMACS Dissociator, filtered through nylon mesh, and layered onto a
Lympholyte-M gradient (Cedarlane Laboratories Ltd., Canada). Lymphocytes were
harvested from the gradient interface. Livers were perfused before removal,
processed in PBS with 1% serum with the GentleMACS, and filtered through nylon
mesh. Samples were washed three times and suspended in 40% Percoll and layered
on 70% Percoll. Lymphocytes were harvested from the gradient interface and
washed once.
NK cell preparation and culture. For in vitro NK cell experiments, congenically
marked splenic NK cells from either control or Ncr1KiPtpn11fl/fl mice were isolated
using the EasySep mouse NK cell isolation kit (Stemcell Technologies Cat. No.
19855) according to the manufacturer’s recommendations. NK cell enrichment was
confirmed by flow cytometry. NK cells were then grown in RPMI 1640 (Life
technologies/Cat number 61870010) supplemented with 10% FCS, 100 U/ml
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, 50 µM 2-
mercaptoethanol (all from Life technologies), and 10 mM HEPES buffer (Bio-
concept) and incubated at 37 °C in 5% CO2 with recombinant mouse IL-15
PeproTech/Cat number 210-15) or IL-2 (PeproTech/Cat number 212-12) for 4 or
5 days in the presence or not of Bcl-2 inhibitor (ABT-199 from BioVision), Mcl-1
inhibitor (S63845 from Selleckchem), Shp-2 inhibitor (SHP099 from Selleckchem),
the MEK (MAP kinase kinase) inhibitor (PD 98059 from Adipogen), or the
mTORC1 inhibitor (Torin2 from Selleckchem) as indicated.
Cell labeling and in vitro proliferation analysis. Labeling of cells with 5 µM cell
trace violet (CTV from Life Technologies) was performed in PBS 1% FCS at 37 °C
for 20 min. In order to analyze proliferation, cell divisions were traced by dye
dilution at the flow cytometer.
In vitro killing assay. RMA, RMA-S, and RMA-H6026 cell lines were maintained
in RPMI 1640 (Life technologies/Cat number 61870010) supplemented with 10%
fetal calf serum (FCS, from PAA), 100 U/ml penicillin, 100 µg/ml streptomycin, 50
µM 2-mercaptoethanol (all from Life Technologies) at 37 °C with 5% CO2.
For NK cells: control and Ncr1Ki Ptpn11fl/fl recipient mice were pre-treated with
150 µg of polyinosinic:polycytidylic acid (polyI:C) (InvivoGen) by intraperitoneal
injection 1 day before the experiment. Splenocytes were collected after mechanical
disruption of the spleen and enriched for NK cells (Stemcell Technologies, Cat. No.
19855). In total, 1 × 104 CTV-labeled target cells (RMA, RMA-S, or RMA-H60)
were then co-cultured with NK cells in NK cell medium in a 96-well plate for 4 h in
the incubator at 37 °C at the following ratios 10:1, 3:1, or 1:1 NK cells per target.
Analysis of the cells was then performed by flow cytometry. RMAs rejection is
shown as percentage of killing.
NK cell degranulation assay. To generate the RMA-m157 transfectants, the
retroviral vector pMX encoding MCMV157 ORF was kindly provided by Dr.
Heusel (Washington University). RMA target cells were retrovirally transduced
and M157 cell surface expression monitored using the anti-M157 mAb Clone
6H1.2.1 (Kindly provided by Dr. Yokoyama Washington University). High
expressors for M157 were cell sorted.
For the stimulation with RMA-m157, splenocytes (1 × 106/well) from Ncr1Tg
Ptpn11fl/fl mice or heterozygote littermate controls were incubated for 6 h with 1 ×
105 RMA cells or RMA-m157 cells in the presence of Golgi-STOP solution and
anti-CD107α antibody. Following incubation, cells were stained with anti-CD3,
NK1.1, anti-Ly49H, and NKp46 antibody. Percentage of YFP+Ly49H+CD107α+
NK cells in each group was determined by flow cytometry.
Seahorse analysis. NK cells were enriched from control and Ncr1Ki Ptpn11fl/fl
mice and stimulated overnight with recombinant mouse IL-15 (50 ng/mL Pepro-
Tech) at 37 °C. The following day, 2.5 × 105 enriched NK cells were seeded in a
Seahorse Bioscience culture plate in DMEM (Sigma) with 10 mM glucose (Sigma),
2 mM glutamine (Life Technology) in a non-CO2 incubator for at least 30 min.
Basal OCR and ECAR were then measured by an XF96 Seahorse Extracellular Flux
Analyzer following the manufacturer’s instruction. Basal OCR and ECAR were
calculated as the mean of the first three time points (basal) for each replicate in
Ncr1Ki Ptpn11wt/wt and Ncr1Ki Ptpn11fl/fl mice. For the calculation of the SRC, the
mean of basal OCR was subtracted to the mean of the three time points at maximal
OCR for each replicate in Ncr1Ki Ptpn11wt/wt and Ncr1Ki Ptpn11fl/fl mice.
NK cell activation in vitro and in vivo. For cytokine stimulation in vitro, sple-
nocytes or enriched NK cells from control and Ncr1Ki Ptpn11fl/fl mice were left
unstimulated or stimulated with recombinant mouse IL-15 (50 ng/mL PeproTech)
for 30 min or 1 h at 37 °C and analyzed for intracellular protein phosphorylation by
flow cytometry or immunoblot analysis. In some experiments as indicated, NK cells
were treated for 30 min with the Shp-2 inhibitor (SHP099 from Selleckchem), the
MEK (MAP kinase kinase) inhibitor (PD 98059 from Adipogen), or the mTORC1
inhibitor (Torin2 from Selleckchem) prior to IL-15 stimulation. NK cells were then
analyzed by flow cytometry or immunoblot analysis, as described in the specific
sections.
For PMA/ionomycin stimulation in vitro, splenocytes from control and Ncr1Ki
Ptpn11fl/fl mice were left unstimulated or stimulated either 15 min with 12.5 nM
PMA plus 0.125 µg/ml ionomycin or 2 h with 50 nM PMA plus 0.5 µg/ml
ionomycin followed by 2 h with Brefeldin A (10 µg/mL Enzo Life Science) for the
detection by flow cytometry of intracellular protein phosphorylation and cytokine
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production, respectively. In cytokine production experiments, anti-CD107α
(LAMP-1) antibody was added at the beginning of incubation to detect NK cell
degranulation.
For IL-15 stimulation in vivo, recombinant mouse IL-15Rα-Fc chimeric
molecule was purchased from R&D Systems and complexed with recombinant
murine IL-15 (PeproTech) for 30 min at 37 °C. Control and Ncr1Ki Ptpn11fl/fl mice,
received 2.5 µg of IL-15 precomplexed with 15 µg of IL-15Rα-Fc in 200 µL of PBS
by intraperitoneal injection. Splenic NK cells were analyzed 1 day post-treatment
by flow cytometry.
For NK cell activation with purified Ly49H antibody, 96-well flat-bottomed
tissue culture plates were coated with purified mouse anti-Ly49H antibody
(Biolegend, Clone 3D10, Cat number 144702) or with IgG1 isotope control
antibody (Biolegend, Clone MG1-45, Cat number 401404) at 10 µg/ml solution in
PBS (without serum) and incubated overnight at 4 °C protected from light. The day
after, coated-plates were washed two times with complete medium. In total, 3 × 105
purified NK cells were plated and stimulated for 5 h in the presence or not of 7 ng/
ml of IL-15. After 2 h of stimulation, 10 µg/mL of Brefeldin A (Enzo Life Science)
was added for the detection by flow cytometry of IFN-γ production.
Flow cytometry. For flow cytometry analysis, cells were pre-incubated with α-
mCD16/32 (2.4G2, 1:100) to block Fc receptors and then surface stained for 20 min
at 4 °C using the antibodies listed in Supplementary Table 1. Streptavidin con-
jugated to different fluorophores were purchased from eBioscience. In some
experiments, dead cells were excluded using 10 µg/ml propidium iodide. Events
were collected on a FACS Canto, Fortessa, or Aria III (BD) and the data were
analyzed using FlowJo software (Tree Star Inc.).
Intracellular flow cytometry stainings. For detection of phosphorylated signaling
proteins, cells were surface stained on ice, fixed with 2% paraformaldehyde at 4 °C
for 15 min, and permeabilized with 90% methanol for 30 min at 4 °C. Intracellular
phospho-stainings were performed 1 h at room temperature in the dark with
antibodies against phospho-STAT5 (Tyr694; D47E7 XP® Rabbit mAb #4322; Cell
Signaling, 1:150), phospho-S6 ribosomal protein (Ser235/236; D57.2.2E; XP®
Rabbit mAb #4858; Cell Signaling, 1:200), phospho-AKT 308 (Thr308; D25E6; XP®
Rabbit mAb #13038; Cell Signaling, 1:100), and phospho-ERK1/2 (Thr202/Tyr204;
D13.14.4E; XP® Rabbit mAb #4370; Cell Signaling, 1:150). A secondary antibody
coupled to an APC-fluorochrome (Donkey F(ab′)2, anti-rabbit, IgG, multi species,
Southern Biotech, 1:250) was used in addition to undirectly conjugated antibodies.
For intracellular staining of Bcl-2 (10C4, eBioscience, 1:100) or Ki67 (SolA15,
eBioscience, 1:100), NK cells were first surface stained, fixed and permeabilized
using the FoxP3 transcription factor staining buffer set of eBioscience (00-5523-00)
according to the manufacturer’s recommendations.
For intracellular cytokine staining, cells were first surface stained, fixed with
Cytofix/Cytoperm (BD Biosciences) and permeabilized in 1X PermWash (BD
Biosciences) or fixed and permeabilized using a standard PFA/saponin protocol. To
conserve eYFP expression during intranuclear staining, samples were prefixed with
fresh 4% PFA (Electron Microscopy Science) for 15 min, fixed using Fixation/
Permeabilization Solution 2 (Miltenyi Biotech) for 40 min, incubated with 1%
Triton X-100 for 15 min, and then stained for 30 min in PBS.
Immunoblotting. To follow the deletion of Shp-2 in NK cells, splenocytes from
Ncr1Tg Ptpn11fl/fl and control animals were sorted using a FACSAria to >95%
efficiency. Populations were collected and lysed in Lysis buffer containing Com-
plete Mini Protease Inhibitor Tablets (Roche Diagnostics). Cellular lysates were
added to SDS/Sample Buffer, boiled, and run on a Ready Gel 4–20% Tris-HCl (Bio-
Rad, Hercules, CA) with 1× SDS-PAGE Running Buffer. Mouse anti-Shp-2 (M163,
Abcam, 1:500) and anti-b-actin antibodies (AC-15, Ambion, 1:1000) were used for
immunoblotting. Membranes were developed with West Pico Chemiluminescent
Substrate (Pierce) and photographed using a ChemiDoc XRS+ System (Bio-Rad).
Following IL-15 stimulation or under resting conditions to assess the deletion of
Shp-2, purified NK cells from Ncr1KiPtpn11fl/fl and control mice were collected and
resuspended directly in sample buffer containing 62.5 mM Tris-HCL pH 7.4, 2.5%
SDS, 0.1 M DTT, 0.002% bromophenol blue, 10% glycerol, 5% 2-mercaptoethanol
for protein lysis and extraction. Protein concentration was determined by
Coomassie blue staining and equal amounts of proteins were loaded. Rabbit
monoclonal antibodies against phospho-STAT5 (Tyr694; D47E7 #4322; Cell
Signaling, 1:1000), phospho-S6 (Ser235/236; D57.2.2E #4858; Cell Signaling,
1:2000), phospho-ERK1/2 (Thr202/Tyr204; D13.14.4E #4370; Cell Signaling,
1:2000), Shp-2 (D50F2 #3397; Cell Signaling, 1:1000), STAT5 (D2O6Y #94205; Cell
signaling, 1:1000), and mouse monoclonal antibody against S6 (54D2 #2317; Cell
Signaling, 1:1000) were used for immunoblotting. The anti-β-actin (from Abcam,
1:2000) polyclonal antibody was used as control. Membranes were revealed using
the fusion SOLO S imaging system from Vilber Lourmat.
MCMV infection. Splenic YFP+ NK cells from Ncr1Tg Ptpn11fl/fl (CD45.2+) mice
were sorted and injected at a 1:1 ratio with sorted splenic NK cells from
B6.SJL (CD45.1+) congenic mice into MCMV infected NK cell-deficient mice
(Ncr1creTgROSA-DTA). Stocks of MCMV salivary gland clone RVG-102 (a gift of
Dr. Hamilton, Duke University) recombinant for GFP under the promoter of the
immediate early gene-1 (ie-1) were generated by homogenizing salivary glands
harvested from CD-1 IGS mice (Charles Rivers, stock #022) infected with 5 × 104
PFU of MCMV. Infections were initiated on day 0 with 5 × 104 plaque-forming
units (PFU) of MCMV in PBS delivered i.p.
Adoptive transfer of NK cells and homeostatic proliferation. Splenic YFP+ NK
cells from Ncr1Tg Ptpn11fl/fl (CD45.2+) mice were sorted and injected at a 1:1 ratio
with sorted splenic NK cells from B6.SJL (CD45.1+) congenic mice into recipient
Rag2−/−Il2Rg−/− mice. Prior to the injection, NK cells were stained for 10 min at
37 ˚C in the dark with 10 µM Cell Proliferation Dye eFuor450 (eBioscience) in PBS.
Recipient mice were allowed to reconstitute for 4 days and sacrificed for analysis.
Quantitative RT-PCR analysis. BM and splenic NK cells were FACS-sorted as
NK1.1+NKp46+CD3−CD19− cells, DP and CD11b SP splenic NK cells were
sorted as NK1.1+NKp46+CD11b+CD27+CD3−CD19− and NK1.1+NKp46
+CD11b+CD27−CD3−CD19− cells, respectively. Sorts were performed using
FACSAria, BD Biosciences.
Total RNA of the cells was then extracted using the TRIzol® reagent (Ambion,
Life Technologies) according to manufacturer’s instructions. Cellular RNA was
extracted using RNeasy kits (Qiagen). Contaminating genomic DNA was removed
using RNase-free DNase (Qiagen), and cDNA was synthesized using M-MLV RT,
RNase H(–) point mutant (Promega, USA) and Random Primers (Invitrogen).
Negative control reactions were performed as above, with the omission of the
enzyme or the cDNA. cDNA was quantified using the LightCycler 480 SYBR Green
I Master (Roche Diagnostics, Germany) on a LightCycler 480 machine (Roche
Diagnostics, Switzerland). Standard cycling was used (45 cycles of 95, 60 and 72 °C-
steps of 10 s each). Negative control reactions were cycled alongside test samples to
ensure the absence of contaminating genomic DNA. Expression was determined
relative to the abundance of the housekeeping gene RNA polymerase II Subunit A
(Polr2a). Data were analyzed and transcript abundance (Gene/Polr2a) and SD
calculated using the LightCycler 480 software release 1.5.0 SP3. The primers used
can be found in Supplementary Table 2.
Statistical analysis. Statistical analyses were performed using Prism software
(GraphPad version 7.0). The Student’s t-test (unless otherwise indicated,
unpaired, two-tailed) was used to compare the significance of differences between
control and Shp-2-deficient conditions, or the indicated experimental groups.
Differences considered significant when p < 0.05 (*), very significant when p <
0.01 (**), highly significant when p < 0.001 (***), and extremely significant when
p < 0.0001 (****).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon request.
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